Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Oncology Vaccine Developer's Lead Programs 'On Track or Better'

The biopharma's two assets are discussed and Q1/19 financial results are provided in a BTIG research report. In a May 13 research note, BTIG analyst Thomas Shrader reported that Gritstone Oncology Inc.'s (GRTS:NASDAQ) lead clinical programs, GRANITE and SL...
Streetwise Reports | May 27, 2019 |

Allogene Therapeutics Shares Climb 30% on Phase 1 Relapsed/Refractory NHL Study Data

Shares of Allogene Therapeutics traded higher and reached a new 52-week high price after the company reported initial results from its Phase 1 relapsed/refractory non-Hodgkin lymphoma trial. Clinical-stage biotechnology company Allogene Therapeutics Inc. (ALLO:NAS...
Streetwise Reports | May 15, 2020 |

Akero Therapeutics Shares Rise on Positive Data from Phase 2a NASH Study

Akero Therapeutics shares traded 28% higher and established a new 52-week high after the company reported that it recorded positive histological data across all Efruxifermin dosage groups in its Phase 2a BALANCED Study in NASH patients. Clinical-stage biotechnology...
Streetwise Reports | July 2, 2020 |

Moderna Shares Rise on the Release of Positive Results from Two mRNA Phase 1 Programs

Shares of Moderna Inc. traded up double-digits today as the firm announced results from its Phase 1 CMV Vaccine Study as well as its Phase 1 data for mRNA-1944 encoding for antibody against the chikungunya virus. This morning clinical-stage biotechnology company Mode...
Streetwise Reports | September 13, 2019 |

Marvel Discovery kicks off 2021 exploration program at Blackfly gold project in Ontario

Fresh off a company rebrand earlier in 2021 and a recent asset spin-off, Marvel Discovery Corp. ( TSX-V: MARV ) (Frankfurt: O4T1) (IMTFF: OTC PINKS) is now ready to move forward with this year’s exploration plans, beginning with one of the most promis...
Richard (Rick) Mills | May 28, 2021 |

First Vanadium Achieves Critical Process Flow Sheet Milestone for Carlin Project

First Vanadium Corp. (FVAN:TSX.V; FVANF:OTCQB) has a large, near-surface vanadium resource (303 million pounds, Indicated category only), with a very good grade (0.615% V2O5) in the great mining jurisdiction of Nevada. The company has 42.4 million shares outstanding & ...
Streetwise Reports | August 15, 2019 |

Central Bank Hypnosis

One look at the chart of the U.S. financial markets against the backdrop of economic paralysis and suffering, and one is immediately filled with a myriad of emotions. Sympathy for those that have been afflicted by the most recent pandemic; fear for the families whose prim...
Streetwise Reports | June 2, 2020 |

DryShips (DRYS): Short sellers blowing wind into the stock's sails?

Shares of DryShips Inc. ( NASDAQ: DRYS , Stock Forum ) finished last week north of their 80-week moving average for the first time in more than two years, after the dry bulk transportation titan said its offshore drilling subsidiary plans to sell about $500 million of sto...
Andrea Kramer | October 28, 2012 |

Currency Wars Are Wars That Gold Wins in the End

July nonfarm payrolls came in line with expectations, confirming the strength of the U.S. labor market. So far so good. With the markets more focused now on the escalation of the trade war triggered by Trump’s tweet on Thursday., she stock market plunged while ...
Arkadiusz Sieron | August 13, 2019 |

Buzz on the Bullboards: Challenges amid inflation and geopolitical tensions

Last week saw the Canadian and U.S. stock markets grappling with a host of challenges, from surging inflation data to escalating tensions in the Middle East. Adding to the mix, a historic trial commenced in New York, as former U.S. President Donald Trump faced allegations...
Jonathon Brown | 5 days ago |
1 2 3 4 5 6 7 8 9 10 ...